Viatris Inc. (NASDAQ:VTRS) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. Barclays Initiates Viatris (VTRS) with Overweight as Pharma Sentiment Improves On December 9, Barclays analyst Glen Santangelo initiated coverage of Viatris Inc. (NASDAQ:VTRS) with an Overweight rating and a $15 price target. The firm launched coverage of the specialty pharmaceuticals industry with a neutral view, noting that investor sentiment is starting to improve as companies place more emphasis on innovat ...

As filed with the Securities and Exchange Commission on December 22, 2025 Registration No. 333-291395 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SRx HEALTH SOLUTIONS, INC. (Exact name of registrant as specified in its charter) (STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION) DELAWARE 5961 83-4284557 (PRIMARY STANDARD INDUSTRIAL CLASSIFICATION CODE NUMBER) (I.R.S. EMPLOYER IDENTIFICA ...

As filed with the Securities and Exchange Commission on December 10, 2025 Registration No. 333-291262 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SRx HEALTH SOLUTIONS, INC. (Exact name of registrant as specified in its charter) (STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION) DELAWARE 5961 83-4284557 (PRIMARY STANDARD INDUSTRIAL CLASSIFICATION CODE NUMBER) (I.R.S. EMPLOYER IDENTIFICA ...

Utilities Sector - Utilities Select Sector SPDR Fund (NYSE:XLU) experienced a dramatic drop of over 50%, with its price falling to $43.54 from a year high of $93.77, indicating volatility in a sector typically considered stable [1][7] - Despite the decline, utility ETFs like XLU are gaining traction due to rising demand for AI-driven data centers and expectations of falling interest rates, which could enhance the sector's attractiveness [1] Healthcare Sector - IMAC Holdings, Inc. (NASDAQ:BACK) faced a steep decline of 42.55%, with its price dropping to $0.1149, significant for a company involved in regenerative and orthopedic therapies [2] - Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) saw its price decrease by 41.88% to $10.99, highlighting challenges in the biotechnology industry where product development and regulatory approval are critical [3] - Ignite Proteomics' collaboration with Inova Health for a biomarker study in late-stage cancers indicates ongoing advancements in precision oncology, which could influence the healthcare landscape [2] Travel Services Sector - Ambitions Enterprise Management Co. L.L.C (NASDAQ:AHMA) experienced a 37.35% decrease in its price to $8.27, reflecting challenges faced by the travel services sector, possibly due to global travel restrictions or economic downturns [4] - The company's subsidiary, MULTIPLE EVENTS L.L.C, has been appointed as the preferred executive service partner for the 19th World Chinese Entrepreneurs Convention, which could enhance its future prospects [4] E-commerce Sector - Jeffs' Brands Ltd (NASDAQ:JFBR) saw its price fall by 36.6% to $1.58, indicating potential challenges in e-commerce or operational issues [5] - The company has entered into a definitive distribution agreement with Scanary Ltd, marking its strategic entry into the global homeland security market, which could open new revenue streams [5] Overall Market Volatility - Significant price movements across various sectors highlight the volatility and challenges faced by companies, with investors closely monitoring developments that may influence future performance [6][7]

Mainboard IPOs - PhysicsWallah is launching an IPO worth Rs 3,480 crore with a price band of Rs 103–109 per share, opening on November 11 and closing on November 13, aiming to enhance its technology platform and expand learning centres [1][8] - Tenneco Clean Air India, a subsidiary of Tenneco Inc., is offering an IPO of Rs 3,600 crore entirely as an offer for sale, with a price band of Rs 378–397 per share, opening on November 12 and closing on November 14 [2][8] - Emmvee Photovoltaic Power is set to open its IPO of Rs 2,900 crore on November 11, priced between Rs 206–217 per share, focusing on India's clean energy sector [5][8] SME IPOs - Mahamaya Lifesciences plans to raise Rs 70.44 crore through its IPO, opening on November 11 and closing on November 13, with a price band of Rs 108–114 per share [6][9] - Workmates Core2Cloud Solution is launching an IPO of Rs 69.84 crore, opening on November 11 and closing on November 13, with a price range of Rs 200–204 per share, specializing in cloud computing and cybersecurity [7][9] Market Overview - The upcoming week will see five IPOs, three from the mainboard and two from the SME segment, with cumulative fundraising exceeding Rs 10,000 crore, testing market liquidity and sentiment [8]

Financial Highlights - Q3 2025 net income attributable to IEP was $287 million, or $049 per depositary unit, compared to $22 million, or $005 per depositary unit, for Q3 2024[6] - Q3 2025 Adjusted EBITDA attributable to IEP was $383 million compared to $183 million for Q3 2024[6] - Indicative net asset value as of September 30, 2025, was approximately $38 billion, an increase of $567 million compared to June 30, 2025[6] - IEP declares third quarter distribution of $050 per depositary unit[6] Segment Performance - Energy segment net income was $258 million in Q3 2025, compared to a loss of $88 million in Q3 2024[9] - Energy segment Adjusted EBITDA was $409 million in Q3 2025, compared to a loss of $38 million in Q3 2024[9] - Investment segment returns were negative 05% for Q3 2025[13, 15] - Automotive Services revenue was $366 million, up $11 million when compared to Q3 2024[25] - Food Packaging Q3 2025 Adjusted EBITDA attributable to IEP decreased by $8 million compared to prior year quarter[32]

Core Insights - Cwm LLC increased its holdings in Supernus Pharmaceuticals by 92.4% in Q2, owning 3,080 shares valued at $97,000 [2] - Other institutional investors also adjusted their stakes, with notable increases from GAMMA Investing LLC (116.7% increase) and State of Wyoming (58.8% increase) [3] - Insider trading activity included CEO Jack A. Khattar selling 140,000 shares for approximately $5.88 million, reducing his ownership by 11.96% [4] Institutional Holdings - Cwm LLC's investment grew to 3,080 shares after acquiring an additional 1,479 shares in Q2 [2] - Caitong International Asset Management and BI Asset Management both acquired new stakes in Q1, valued at approximately $41,000 and $46,000 respectively [3] - State of Wyoming increased its holdings to 4,754 shares, worth $156,000 after buying 1,761 additional shares [3] Insider Activity - CEO Jack A. Khattar sold 140,000 shares at an average price of $42.02, totaling $5,882,800, leaving him with 1,030,183 shares valued at approximately $43.29 million [4] - SVP Frank Mottola sold 14,000 shares at an average price of $44.51, resulting in a total transaction of $623,140 and a 47.46% decrease in ownership [4] - In the last three months, insiders sold 362,741 shares valued at $16.39 million, with insiders owning 8.80% of the stock [4] Stock Performance - Supernus Pharmaceuticals shares opened at $55.13, with a market capitalization of $3.09 billion and a P/E ratio of 47.94 [5] - The stock has a 1-year low of $29.16 and a high of $57.65, with a fifty-day moving average of $48.02 [5] Analyst Ratings - Bank of America initiated coverage with a "buy" rating and a target price of $65.00 [6] - Cantor Fitzgerald raised its price target from $46.00 to $63.00, maintaining an "overweight" rating [6] - The consensus rating for Supernus Pharmaceuticals is "Buy" with an average target price of $63.25 [6] Company Overview - Supernus Pharmaceuticals focuses on developing and commercializing products for central nervous system diseases [8] - Key products include Trokendi XR for epilepsy and migraine prophylaxis, and Oxtellar XR for partial onset seizures [8]

Core Viewpoint - Collegium Pharmaceutical (COLL) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling actions that affect stock prices [4]. Company Performance and Outlook - The upgrade for Collegium Pharmaceutical reflects an improvement in its underlying business, suggesting that investors may push the stock price higher due to this positive trend [5][10]. - The Zacks Consensus Estimate for Collegium Pharmaceutical indicates expected earnings of $7.03 per share for the fiscal year ending December 2025, with a 1.8% increase in estimates over the past three months [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, positioning Collegium Pharmaceutical among the best candidates for potential market-beating returns [9][10].

Core Insights - CROSSJECT reported its financial results for the first half of 2025, highlighting progress in regulatory activities and financial performance [3][4][9]. Financial Performance - The company recorded revenues of €8,038,000 for H1 2025, an increase from €5,766,000 in H1 2024 [13]. - R&D reimbursements from BARDA rose significantly to €6,584,000 in H1 2025, compared to €3,064,000 in H1 2024, reflecting increased R&D activities [13][19]. - The operating loss improved to €5,139,000 in H1 2025 from €6,719,000 in H1 2024, indicating better cost management [14]. - The net loss for the period was €4,868,000, down from €6,402,000 in the same period last year [14]. Regulatory and Development Activities - CROSSJECT continued its regulatory efforts with BARDA to obtain Emergency Use Authorization (EUA) for ZEPIZURE® in the U.S. [4][9]. - The company produced validation batches in collaboration with its CDMO partner EUROFINS, which are part of the EUA dossier [5]. - In September 2025, CROSSJECT secured an €11.3 million extension of R&D funding from the U.S. government [5]. Production and Innovation - The company finalized the development of the ZENEO® Nest module to enhance aseptic filling operations, preparing for increased production volumes [7]. - CROSSJECT maintained a cash position of €6.3 million as of June 30, 2025, down from €7.0 million at the end of 2024, reflecting effective resource management [9]. Strategic Collaborations - The company strengthened its marketing strategy for ZEPIZURE® by collaborating with opinion leaders in epilepsy and emergency medicine [8]. - In preparation for potential FDA inspections, BARDA conducted mock audits during the summer [10].

Core Insights - Santhera Pharmaceuticals reported a significant increase in total revenue by 70% to CHF 24 million for the first half of 2025, driven by strong sales of AGAMREE and growing royalty revenues [5][23][24] - The company is advancing the global rollout of AGAMREE, particularly in the US, Germany, Austria, and the UK, with expectations for continued growth in sales and market share [3][6][14] - Santhera has secured additional financing of approximately CHF 20 million to support increased product demand and global launches, maintaining a cash-flow break-even guidance for mid-2026 [21][31] Financial Performance - Total revenue increased to CHF 24 million from CHF 14.1 million in H1 2024, with product sales rising 76% to CHF 11.6 million [5][23][24] - Royalties from licensing partners surged to CHF 5.4 million, a 500% increase compared to CHF 0.9 million in H1 2024, indicating strong growth in the US and China [5][24] - Operating loss widened to CHF 35.4 million from CHF 17.7 million in H1 2024, primarily due to a one-time milestone payment of USD 25 million [31][28] Market Expansion - AGAMREE has achieved over 40% market penetration among steroid-using DMD patients in Germany, with Austria exceeding 50% market share [6][7] - The UK market has positively contributed following the nationwide launch in April 2025, supported by favorable NICE guidance [8] - Santhera is actively pursuing pricing and reimbursement discussions in Spain, Italy, and the Nordic regions, with launches expected from Q4 2025 to Q1 2026 [10][11][12] Strategic Initiatives - The company is focusing on expanding its distribution agreements across multiple regions, including five Gulf Cooperation Council countries, India, and Türkiye [15][17] - Santhera plans to present long-term clinical outcomes from the GUARDIAN study in early Q4 2025, which may further support AGAMREE's market position [18] - The company is not planning near-term investments in additional indication expansions for AGAMREE but is looking to leverage partnerships for future studies [19] Leadership and Governance - Santhera appointed Catherine Isted as CFO in February 2025 and Dr. Melanie Rolli to the Board in May 2025, enhancing its leadership team with experienced professionals [20]